Supplementary material 1: Outcome definition

VAP surveillance in Brazil - ANVISA criteria(9)

 Patient on mechanical ventilator (MV) for a period longer than two consecutive days (i.e., starting from day 3, where day 1 is the day of MV installation) and who, on the date of infection, was either using MV or had it removed the day before.

AND

- 2. Without underlying heart or lung disease, with ONE or more serial imaging exams showing any of the following findings, whether new, persistent, or progressive:
 - Infiltration
 - Opacification/consolidation
 - Cavitation
 - Pneumatocele

AND

- 3. At least ONE of the following signs or symptoms:
 - Fever (temperature: >38°C) without any other associated cause.
 - Leukopenia (<4000 cells/mm3) or leukocytosis (>12000 cells/mm3 or ≥15000 cells/mm³ with left shift and more than 10% of immature neutrophils in children ≤14 years old).
 - Change in level of consciousness without any other apparent cause in patients ≥70 years old.

AND

- 4. At least TWO of the following signs or symptoms:
 - Onset of purulent secretion or change in characteristics of the secretion or increase in respiratory secretion or increase in the need for suctioning.
 - Apnea, tachypnea, dyspnea, or cough (new episode or worsening).
 - Auscultation with wheezing, snoring, or crackles (new episode or worsening).
 - Worsening of gas exchange, desaturation, increased oxygen demand or increased respiratory rate or changes in ventilatory parameters for at least 2 days.

AND

• The signs/symptoms and imaging findings occurred during the window period of infection.

OR

5. ONE of the criteria above (Item 4) AND at least ONE of the following results:

- Positive blood culture4 without another focus of infection.
- Positive culture of pleural fluid.
- Quantitative culture positive for pulmonary secretion obtained by a procedure

with minimal potential for contamination (bronchoalveolar lavage, protected brush and endotracheal aspirate5).

• In bacterioscopy of bronchoalveolar lavage, finding of ≥ 5% of leukocytes and macrophages containing microorganisms (presence of intracellular bacteria).

• Positive culture of lung tissue.

• Histopathological examination showing at least one of the following evidences of pneumonia:

- Formation of abscess or consolidation focus with polymorphonuclear infiltration in bronchioles and alveoli;
- Evidence of invasion of lung parenchyma by hyphae or pseudohyphae.

• Virus, Bordetella, Legionella, Chlamydophila, or Mycoplasma identified from secretion or lung tissue culture, or identified by microbiological testing performed for clinical diagnosis or treatment purposes.

• 4-fold increase in IgG values in serology for pathogen (example: Chlamydophila).

• 4-fold increase in IgG values in serology for Legionella pneumophila serogroup I titrated ≥ 1:128 in acute and convalescent phases by indirect immunofluorescence.

• Detection of antigen of Legionella pneumophila serogroup I in urine.

AND

6. The signs/symptoms and imaging/laboratory tests occurred during the window period of infection.

VAE surveillance in USA - NHSN criteria(12)

VAEs are identified by using a combination of objective criteria: deterioration in respiratory status after a period of stability or improvement on the ventilator, evidence of infection or inflammation, and laboratory evidence of respiratory infection. There are three definition tiers within the VAE algorithm: 1) Ventilator-Associated Condition (VAC); 2) Infectionrelated Ventilator-Associated Complication (IVAC); and 3) Possible VAP (PVAP).

1. Ventilator-Associated Condition (VAC):

Patient has a baseline period of stability or improvement on the ventilator, defined by \geq 2 calendar days of stable or decreasing daily minimum* FiO2 or PEEP values. The baseline period is defined as the 2 calendar days immediately preceding the first day of increased daily minimum PEEP or FiO2.

* Daily minimum defined by lowest value of FiO2 or PEEP during a calendar day that is maintained for > 1 hour

AND

After a period of stability or improvement on the ventilator, the patient has at least one of the following indicators of worsening oxygenation:

- Increase in daily minimum FiO2 of ≥ 0.20 (20 points) over the daily minimum FiO2 of the first day in the baseline period, sustained for ≥ 2 calendar days.
- Increase in daily minimum PEEP values of ≥ 3 cmH2O over the daily minimum PEEP of the first day in the baseline period⁺, sustained for ≥ 2 calendar days.
- 2. Infection-related Ventilator-Associated Complication (IVAC):

Patient meets criteria for VAC AND on or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, the patient meets both of the following criteria:

Temperature > 38 °C or < 36°C, OR white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 cells/mm3.

AND

• A new antimicrobial agent is started and is continued for ≥ 4 qualifying antimicrobial days (QAD).

Possible Ventilator-Associated Pneumonia (PVAP)

Patients meet criteria for IVAC AND On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, ONE of the following criteria is met:

Criterion 1: Positive culture of one of the following specimens, meeting quantitative or semi-quantitative thresholds without requirement for purulent respiratory secretions:

- Endotracheal aspirate, ≥ 105 CFU/ml or corresponding semi-quantitative result
- Bronchoalveolar lavage, ≥ 104 CFU/ml or corresponding semi-quantitative result
- Lung tissue, ≥ 104 CFU/g or corresponding semi-quantitative result
- Protected specimen brush, ≥ 103 CFU/ml or corresponding semi-quantitative result

Criterion 2: Purulent respiratory secretions (defined as secretions from the lungs, bronchi, or trachea that contain \geq 25 neutrophils and \leq 10 squamous epithelial cells per low power field [lpf, x100]) PLUS organism identified from one of the following specimens (to include qualitative culture, or quantitative/semiquantitative culture without sufficient growth to meet Criterion #1):

- Sputum
- Endotracheal aspirate
- Bronchoalveolar lavage
- Lung tissue
- Protected specimen brush

Criterion 3: One of the following positive tests:

 Organism identified from pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; pleural fluid specimens collected after a chest tube is repositioned or from a chest tube in place > 24 hours are not eligible for PVAP)

• Lung histopathology, defined as: 1) abscess formation or foci of consolidation with intense neutrophil accumulation in bronchioles and alveoli; 2) evidence of lung parenchyma invasion by fungi (hyphae, pseudohyphae, or yeast forms); 3) evidence of infection with the viral pathogens listed below based on results of immunohistochemical assays, cytology, or microscopy performed on lung tissue

• Diagnostic test for Legionella species

• Diagnostic test on respiratory secretions for influenza virus, respiratory syncytial virus, adenovirus, parainfluenza virus, rhinovirus, human metapneumovirus, coronavirus.